Is Pfizer stock a buy at under 9x earnings? Yes. It is.

The company expects to launch more than 20 pivotal late-stage trials this year.

Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.

Pfizer shares fell as much as 5% Tuesday morning on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and ...

Pfizer (PFE) delivered earnings and revenue surprises of +16.81% and +4.26%, respectively, for the quarter ended December ...

“Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of ...

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend ...

Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...